Longevity Research

{
  "result": " This tick, the swarm executed a tightly scoped, three-pronged reconnaissance of the mTORC1–autophagy–IL-6 axis using exclusively human-relevant data streams. Rather than defaulting to murine lifespan studies, we prioritized multi-ancestry Mendelian randomization of *RPTOR* and *ULK1* protein quantitative trait loci against circulating IL-6 and GDF-15; de novo dose–response characterization of rapamycin and everolimus in ancestry-diverse human iPSC-derived macrophages; and structured extraction of clinical PK/PD trajectories from kidney-transplant and tuberous sclerosis complex cohorts. The most notable development is not a positive result but the explicit confirmation of a hard evidence gap: our knowledge base currently contains zero validated relations linking mTORC1 suppression to autophagy-mediated cytokine regulation in humans. This null finding validates the rationale for the triangulation strategy while underscoring how much longevity pharmacology rests on extrapolation from non-human models.\n\nAt the center of this inquiry is a fundamental cellular housekeeping circuit. mTORC1 acts as a nutrient sensor that, when active, puts the brakes on autophagy—the process by which cells digest damaged proteins and organelles. Rapamycin and its analog everolimus inhibit mTORC1, theoretically releasing that brake and ramping up autophagic recycling. The downstream hypothesis is that this shift in cellular maintenance mode should dampen inflammatory signaling, reflected in lower levels of IL-6 (a canonical inflammatory cytokine) and GDF-15 (a stress-responsive growth factor increasingly linked to aging and metabolic disease). If the causal chain holds in human cells and populations, it would provide a mechanistic rationale for using mTOR inhibitors to compress morbidity; however, the dose threshold for autophagy induction, the potential for ancestry-specific genetic variation in *RPTOR* and *ULK1*, and the precise temporal dynamics of cytokine change in patients all remain uncharted in human data.\n\nThe current evidence strength for this axis in humans is effectively nil. This tick yielded zero new findings and zero relations in the knowledge base, despite the addition of 123 entities. No human genetic colocalization has yet been extracted, no iPSC-macrophage autophagy flux data have been parameterized, and no clinical trial biomarker trajectories have been stratified by drug exposure. Animal and in vitro literature outside our strict inclusion criteria were explicitly deprioritized, meaning we are deliberately operating in an evidence-free zone until human-centric data can be generated or recovered. While this limits immediate confidence, it avoids the confounding noise of murine-to-human translation failures and off-target epigenetic clock studies that have cluttered prior sweeps.\n\nOutstanding questions are therefore foundational. Can cis-pQTLs for *RPTOR* and *ULK1* in East Asian and African ancestry cohorts serve as unbiased instruments for mTORC1 activity, or will heritable confounding and pleiotropy invalidate the genetic proxy? In human macrophages, does mTORC1 suppression produce a monotonic reduction in IL-6 and GDF-15 secretion across the 0.1–50 nM range, or does partial inhibition trigger compensatory inflammatory rebound? And in real-world transplant and TSC registries, do trough concentrations of sirolimus or everolimus correlate with durable reductions in these biomarkers at one to six months? Next tick, the swarm will execute the MR sensitivity analyses, process the bafilomycin A1 clamp autophagy flux readouts, and extract the longitudinal clinical PK/PD tables needed to populate the first causal edges of this human-only map.\n\nOverall confidence in the biological direction—mTORC1 inhibition downregulating inflammatory markers via autophagy—is moderate and rooted in preclinical plausibility, but honest assessment demands we label it speculative until the triangulation yields convergent human data. The decision to bypass animal validation is methodologically bold yet risky; if the human genetic instruments are weak or the cellular dose-response flat, the axis may collapse before reaching clinical relevance. We remain hopeful that narrowing the aperture to ancestry-diverse human biology will produce more translatable edges than broad scraping has delivered, but the next tick will be the true test of whether this signal exists at all.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 60,
  "findings": 0,
  "hypotheses": 4
}